Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,971
  • Shares Outstanding, K 255,883
  • Annual Sales, $ 60,280 K
  • Annual Income, $ -113,870 K
  • EBIT $ -45 M
  • EBITDA $ -35 M
  • 60-Month Beta 2.52
  • Price/Sales 0.40
  • Price/Cash Flow N/A
  • Price/Book 0.89
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings $-0.07 on 11/13/24
  • Next Earnings Date 03/20/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 331.58% ( +65.44%)
  • Historical Volatility 141.48%
  • IV Percentile 85%
  • IV Rank 48.18%
  • IV High 675.50% on 03/17/25
  • IV Low 11.81% on 06/11/24
  • Put/Call Vol Ratio 1.90
  • Today's Volume 58
  • Volume Avg (30-Day) 58
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,974
  • Open Int (30-Day) 4,246

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +555,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2231 +3.14%
on 03/26/25
0.6065 -62.06%
on 02/27/25
-0.3569 (-60.80%)
since 02/26/25
3-Month
0.2231 +3.14%
on 03/26/25
0.6850 -66.41%
on 01/06/25
-0.3376 (-59.47%)
since 12/26/24
52-Week
0.2231 +3.14%
on 03/26/25
1.6500 -86.05%
on 03/28/24
-1.2899 (-84.86%)
since 03/26/24

Most Recent Stories

More News
Adaptimmune Provides Q4 and Full Year 2024 Business Update

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission...

ADAP : 0.2301 (-7.96%)
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 0.2301 (-7.96%)
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers...

ADAP : 0.2301 (-7.96%)
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assetsAdaptimmune Allo-T program to be featured...

ADAP : 0.2301 (-7.96%)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from the...

ADAP : 0.2301 (-7.96%)
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcomaPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December...

ADAP : 0.2301 (-7.96%)
Adaptimmune Reports Q3 2024 Financial and Business Updates

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number...

ADAP : 0.2301 (-7.96%)
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses (21/64)Data to be presented...

ADAP : 0.2301 (-7.96%)
Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers...

ADAP : 0.2301 (-7.96%)
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...

ADAP : 0.2301 (-7.96%)

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.2856
2nd Resistance Point 0.2717
1st Resistance Point 0.2509
Last Price 0.2301
1st Support Level 0.2162
2nd Support Level 0.2023
3rd Support Level 0.1815

See More

52-Week High 1.6500
Fibonacci 61.8% 1.1049
Fibonacci 50% 0.9366
Fibonacci 38.2% 0.7682
Last Price 0.2301
52-Week Low 0.2231

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar